| Literature DB >> 30822103 |
K B Biello1,2,3, A Edeza1, P Salhaney2, D L Biancarelli4, M J Mimiaga1,2,3,5, M L Drainoni4,6,7, E S Childs4, A R Bazzi8.
Abstract
The efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention has been established among people who inject drugs (PWID). HIV uninfected, at risk PWID, could likely benefit from long-acting injectable formulations of PrEP ("LAI-PrEP"); however, its acceptability in this population has not been previously documented. Thirty-three HIV-uninfected PWID in the U.S. Northeast completed an in-depth interview regarding perceived acceptability of LAI-PrEP. Coded data were synthesized using deductive thematic analysis. The majority of PWID interviewed believed LAI-PrEP would be acceptable. Participants perceived that receiving injections every two months would reduce barriers to daily oral PrEP adherence, including forgetting while "high" and safeguarding pills when homeless. A few participants expressed concerns regarding LAI-PrEP, including medical mistrust, a concern that injections could alter their "high" or be "triggering" for PWID. LAI-PrEP has the potential to reduce HIV among PWID; however, their perspectives are largely absent from research examining its efficacy, representing a missed opportunity.Entities:
Keywords: HIV infections; intravenous; pre-exposure prophylaxis; risk factors; sexual behavior; substance abuse
Mesh:
Substances:
Year: 2019 PMID: 30822103 PMCID: PMC6663616 DOI: 10.1080/09540121.2019.1587356
Source DB: PubMed Journal: AIDS Care ISSN: 0954-0121